TG Therapeutics registers two Phase 2 ublituximab trials, in schizophrenia and myasthenia gravis

TG Therapeutics added two Phase 2 studies of ublituximab to the registry this week, both recruiting.

• A Phase 2 study, "Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia" (NCT07680946), is testing ublituximab's effect on Positive and Negative Syndrome Scale total score in participants with schizophrenia.¹ The study plans to enroll 60 participants¹ and is recruiting at two sites in the United States, in Little Rock, Arkansas, and Richardson, Texas.
• A Phase 2 study, "A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis" (NCT07673744), will assess ublituximab's efficacy in adult participants with MG responding to treatment with efgartigimod.² The trial expects to enroll 120 participants² and its primary outcome is time to onset of a clinical worsening event, up to Week 24.²